Ticlopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).
View/ Open
Date
2012Author
Jacob, S
Dunn, B.L
Qureshi, Z.P
Bandarenko, N
Kwaan, H.C
Pandey, D.K
McKoy, J.M
Barnato, S.E
Winters, J.L
Cursio, J.F
Weiss, I
Raife, T.J
Carey, P.M
Sarode, R
Kiss, J.E
Danielson, C
Ortel, T.L
Clark, W.F
Rock, G
Matsumoto, M
Fujimura, Y
Zheng, X.L
Chen, H
Chen, F
Armstrong, J.M
Raisch, D.W
Bennett, C.L
Type
ArticleLanguage
enMetadata
Show full item recordAbstract
Thienopyridine-derivatives (ticlopidine, clopidogrel, and prasugrel) are the primary antiplatelet agents. Thrombotic thrombocytopenic purpura (TTP) is a rare drug-associated syndrome, with the thienopyridines being the most common drugs implicated in this syndrome. We reviewed 20 years of information on clinical, epidemiologic, and laboratory findings for thienopyridine-associated TTP. Four, 11, and 11 cases of thienopyridine-associated TTP were reported in the first year of marketing of ticlopidine (1989), clopidogrel (1998), and prasugrel (2010), respectively. As of 2011, the FDA received reports of 97 ticlopidine-, 197 clopidogrel-, and 14 prasugrel-associated TTP cases. Severe deficiency of ADAMTS-13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) was present in 80% and antibodies to 100% of these TTP patients on ticlopidine, 0% of the patients with clopidogrel-associated TTP (p < 0.05), and an unknown percentage of patients with prasugrel-associated TTP. TTP is associated with use of each of the three thienopyridines, although the mechanistic pathways may differ.
URI
http://hinari-gw.who.int/whalecomwww.ncbi.nlm.nih.gov/whalecom0/pubmed/23111862http://erepository.uonbi.ac.ke:8080/xmlui/handle/123456789/16963
Citation
Semin Thromb Hemost. 2012 Nov;38(8):845-53. doi: 10.1055/s-0032-1328894. Epub 2012 Oct 30.Collections
- Faculty of Health Sciences (FHS) [10377]